Clozapine: TRS Titration

Treatment-resistant schizophrenia dosing with mandatory ANC surveillance for agranulocytosis risk.

Current Stage

—

—

Dose phase

—

ANC safety status

—

Agranulocytosis risk

—

Monitoring needed

—

Clozapine dose (mg/day)12.5

ANC level (cells/µL)3000

Dose titration curve

Normal ANC zone (>1500)

Moderate neutropenia zone

Agranulocytosis risk zone (<500)

Weekly ANC sample marker

Scroll for details

Confirming Treatment-Resistant Schizophrenia

Two adequate antipsychotic trials must fail before clozapine is considered.

2: Trials required (Adequate dose and duration)
6–8 wks: Trial length (Each antipsychotic trial)
~30%: TRS prevalence (Of schizophrenia patients)
~60%: Response rate (On clozapine after TRS)

Defining treatment resistance

Placeholder: criteria require two failed trials of adequate dose and duration.

Baseline ANC Testing and Titration Start

A normal baseline ANC is required before the first dose is given.

12.5mg: Starting dose (Once or twice daily)
1500: Baseline ANC min (Cells/µL required)
25–50mg: Titration step (Per day, gradually)
300–450mg: Target range (Typical daily dose)

Starting the titration schedule

Placeholder: dose begins low and rises gradually while ANC is confirmed normal.

Weekly ANC Monitoring Through Week 18

ANC is drawn weekly for the first 18 weeks of therapy.

18 wks: Monitoring window (Weekly ANC draws)
Monthly: After week 18 (If ANC stays normal)
Required: REMS program (US clozapine registry)
>48h: Missed dose rule (Requires retitration)

Mandatory ANC surveillance

Placeholder: weekly bloodwork tracks neutrophil counts during early treatment.

Optimizing Dose Within the Therapeutic Window

Dose is adjusted upward toward efficacy while watching tolerability.

350ng/mL: Plasma level target (Trough level goal)
900mg: Max daily dose (Upper labeled limit)
Sedation: Common side effect (Dose-dependent)
Dose-linked: Seizure risk (Higher at high dose)

Balancing efficacy and tolerability

Placeholder: dose optimization weighs response against side-effect burden.

Recognizing and Responding to Agranulocytosis Risk

A falling ANC triggers mandatory dose hold or permanent discontinuation.

<500: Agranulocytosis (ANC cells/µL threshold)
~0.8%: Incidence (Of treated patients)
Wks 4–18: Peak risk period (Highest incidence window)
Rarely: Rechallenge (After severe neutropenia)

Responding to neutrophil decline

Placeholder: falling ANC mandates increased monitoring or stopping clozapine.

Placeholder: ANC below 500 requires immediate discontinuation and daily counts.